Protara Therapeutics (TARA) Non-Current Assets (2013 - 2026)

Protara Therapeutics' Non-Current Assets history runs 14 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 23.55% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $142.7 million (up 104.57% YoY), while the FY2025 annual figure was $50.0 million, up 437.31% from the prior year.
• Non-Current Assets was $51.9 million for Q1 2026 at Protara Therapeutics, up from $50.0 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $70.6 million in Q1 2022 to a low of $9.0 million in Q3 2025.
• Historically, Non-Current Assets has averaged $27.5 million across 5 years, with a median of $11.8 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets sank 83.29% in 2023, then soared 437.31% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $27.1 million in 2022, then sank by 62.24% to $10.2 million in 2023, then fell by 9.27% to $9.3 million in 2024, then jumped by 437.31% to $50.0 million in 2025, then grew by 3.93% to $51.9 million in 2026.
• The last three Non-Current Assets figures came in at $51.9 million (Q1 2026), $50.0 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.